DDrare: Database of Drug Development for Rare Diseases

Searched query = "Huntington disease", "Huntington chorea"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = (2)-epigallocatechin-3-gallate (EGCG); 20 mg BID of PF-02545920; 20mg daily citalopram; 5-Chloro-1,2-dihydro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-3-quinolinecarboxamide sodium; ACR16; ACR16 10 mg; ACR16 22.5 mg; ACR16 45 mg; ACR16 hydrochloride, ASP2314 hydrochloride, FR310826; AFQ056; ANX005; Alprazolam; Amantadine; Anti-Parkinson medication; Atomoxetine; Autologous Stem Cell; BEVANTOLOL HYDROCHLORIDE; BN82451B; BN8251B; Bevantolol; Biotin; Blood sample; Bupropion; CBD; CKD-504; CYSTAGON; Calvan® 100 mg; Cannabidiol; Cellavita HD Higher dose; Cellavita HD Lower Dose; Cellavita HD higher dose; Cellavita HD lower dose; Cellavita-HD; Citalopram; CoQ10; Coenzyme Q10; Creatine; Creatine Monohydrate; Creatine monohydrate; Cystagon; Cysteamine; Cysteamine Bitartrate; DM; Delta-9-tetrahydrocannabinol; Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD); Deutetrabenazine; Deutetrabenazine Oral Tablet [Austedo]; Device: BioStamp nPoint device; Device: Deep Brain Stimulation; Dextromethorphan; Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg); Digoxin; Dimebon; Dimebon (latrepirdine); Dimebon + Dextromethorphan; Dimebon + Ketoconazole; Dimebon + Omeprazole; Dimebon Dihydrochloride; Dimebon IR; Dimebon IR Tablet; Dimebon MR1; Dimebon MR2; Dimebon MR3; Dimebon MR4; Dimebon Transdermal; Dimebon alone; Dimebon dihydrochloride; Divalproex; EGCG; EPA; Epigallocatechin; Ethyl Icosapent; Ethyl-EPA; Ethyl-EPA (Miraxion™); Ethyl-Icosapent; Fenofibrate; GSK356278; Graft intracerebral of foetal neurons; HYPERIUM; Haloperidol; High doses of Thiamine y Biotin; Hyperium; ISIS 443139 10 mg; ISIS 443139 120 mg; ISIS 443139 30 mg; ISIS 443139 60 mg; ISIS 443139 90 mg; Icosapent; Ketoconazole; LAQUINIMOD; LAX-101; Laquinimod; Laquinimod capsules 0.5 mg; Latrepirdine; Lithium; Melatonin; Memantine; Minocycline; Moderate doses of Thiamine y Biotin; N.a.; Neflamapimod; Nilotinib; Nilotinib 150 MG; OMS643762; OSU6162 similar to (-)-OSU 6162; Olanzapine; Omeprazole; Other: 31-Phosphorus RMN Spectroscopy; PBF-999; PBF-999 / 160 mg; PBF-999 / 320 mg; PBT2; PF-02545920; PL101; PRIDOPIDINE HYDROCHLORIDE; Phenylbutyrate; Phosphorus; Pridiopidine; Pridopidina; Pridopidine; Pridopidine (90 mg); Quinidine; RG6042, formerly ISIS 443139, IONIS-HTTRx; RO7234292; RO7234292 (RG6042); RP 103; RP103; Ramelteon; Resveratrol; Rilmenidine; Riluzole; Risperidone; Ro 723-4292/F02; Rolipram; SAGE-718; SBT-020; SD-809; SEN0014196; SEN0014196 (High Dose); SEN0014196 (Low Dose); SOM3355 100mg BID; SOM3355 200mg BID; SRX246; SS-20; Selisistat; Sodium phenylbutyrate; THC; TV-5600; TV-7820; Tetrabenazine; Tetrabenazine withdrawal; Tetrahydrocannabinol; Thiamine; Tiapridal; Tominersen; Triheptanoin; Triheptanoin 1g/kg/day; Triheptanoin oil; UX007; Ubiquinol; Ursodiol; VX-745; VX15/2503; Valbenazine; WVE-120101; WVE-120102; Warfarin; Xenazine; Zoloft; [123I]MNI-420; [18F]FPEB

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04071639 (ClinicalTrials.gov)	October 20, 2019	26/8/2019	Symptomatic Therapy for Patients With Huntington's Disease	Randomized Clinical Trial to Evaluate the Efficacy and Safety of Symptomatic Drug Therapy for Mild to Moderate Huntington's Disease Patients	Huntington Disease	Drug: Haloperidol;Drug: Risperidone;Drug: Zoloft;Drug: Coenzyme Q10	Second Affiliated Hospital, School of Medicine, Zhejiang University	NULL	Recruiting	N/A	N/A	All	100	Phase 1	China
2	NCT00920699 (ClinicalTrials.gov)	February 2010	9/6/2009	Study in PRE-manifest Huntington's Disease of Coenzyme Q10 (UbiquinonE) Leading to Preventive Trials (PREQUEL)	A Multi-Center, Double-Blind, Randomized, Parallel Group Tolerability Study of Coenzyme Q10 (UbiquinonE)in PRE-manifest Huntington's Disease	Huntington's Disease	Drug: CoQ10	Johns Hopkins University	National Institute of Neurological Disorders and Stroke (NINDS)	Completed	18 Years	N/A	All	90	Phase 2	United States
3	NCT00608881 (ClinicalTrials.gov)	March 2008	4/2/2008	Coenzyme Q10 in Huntington's Disease (HD)	Coenzyme Q10 in Huntington's Disease (HD)	Huntington's Disease	Drug: coenzyme Q10;Other: placebo	Massachusetts General Hospital	National Institute of Neurological Disorders and Stroke (NINDS);University of Rochester	Terminated	16 Years	N/A	All	609	Phase 3	United States;Australia;Canada

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04071639
(ClinicalTrials.gov)

October 20, 2019

26/8/2019

Symptomatic Therapy for Patients With Huntington's Disease

Randomized Clinical Trial to Evaluate the Efficacy and Safety of Symptomatic Drug Therapy for Mild to Moderate Huntington's Disease Patients

Huntington Disease

Drug: Haloperidol;Drug: Risperidone;Drug: Zoloft;Drug: Coenzyme Q10

Second Affiliated Hospital, School of Medicine, Zhejiang University

NULL

Recruiting

N/A

All

100

Phase 1

China

NCT00920699
(ClinicalTrials.gov)

February 2010

9/6/2009

Study in PRE-manifest Huntington's Disease of Coenzyme Q10 (UbiquinonE) Leading to Preventive Trials (PREQUEL)

A Multi-Center, Double-Blind, Randomized, Parallel Group Tolerability Study of Coenzyme Q10 (UbiquinonE)in PRE-manifest Huntington's Disease

Huntington's Disease

Drug: CoQ10

Johns Hopkins University

National Institute of Neurological Disorders and Stroke (NINDS)

Completed

18 Years

N/A

All

Phase 2

United States

NCT00608881
(ClinicalTrials.gov)

March 2008

4/2/2008

Coenzyme Q10 in Huntington's Disease (HD)

Huntington's Disease

Drug: coenzyme Q10;Other: placebo

Massachusetts General Hospital

National Institute of Neurological Disorders and Stroke (NINDS);University of Rochester

Terminated

16 Years

N/A

All

609

Phase 3

United States;Australia;Canada